Euroapi

Euroapi is a specialized pharmaceutical entity focused on the development, manufacturing, and supply of active pharmaceutical ingredients (APIs) and related solutions for human and veterinary medicine. Founded in 2021, the company provides comprehensive contract development and manufacturing services to global biotechnology and healthcare organizations. Euroapi leverages advanced production technologies to support drug development, ensuring high-quality output across its diverse portfolio of molecules and therapeutic ingredients. The firm emphasizes supply chain reliability, sustainability, and technical innovation to strengthen the global healthcare value chain.

Operating with a workforce of 1,000-5,000 employees, Euroapi maintains a robust operational footprint across 2 locations. The company integrates large-scale commercial manufacturing with custom microbial process development and R&D capabilities to meet complex patient needs. Meet Euroapi's team to understand the organizational structure and leadership driving these technical operations. By combining engineering expertise with biochemical precision, the company delivers high-quality custom pharmaceutical ingredients that adhere to stringent regulatory standards, supporting both western and international therapeutic markets.

Listed on the Euronext Paris under the ticker EPA: EAPI, Euroapi demonstrates significant market presence with annual revenue of $975.0M. The company recently secured $474.0M in debt funding from Sanofi, reflecting its strategic position within the pharmaceutical sector. Explore financial highlights to review detailed fiscal metrics and funding history. As a key player in the B2B pharmaceutical space, Euroapi continues to expand its influence through innovation in drug production and active ingredient synthesis, maintaining a competitive edge in the evolving global healthcare landscape.